The stock of Trevena Inc (NASDAQ:TRVN) reached all time low today, Nov, 4 and still has $3.65 target or 10.00% below today’s $4.05 share price. This indicates more downside for the $206.99 million company. This technical setup was reported by Barchart.com. If the $3.65 PT is reached, the company will be worth $20.70M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 307,258 shares traded hands or 11.90% up from the average. Trevena Inc (NASDAQ:TRVN) has declined 56.11% since April 4, 2016 and is downtrending. It has underperformed by 57.20% the S&P500.
Analysts await Trevena Inc (NASDAQ:TRVN) to report earnings on November, 8. They expect $-0.37 EPS, down 54.17% or $0.13 from last year’s $-0.24 per share. After $-0.37 actual EPS reported by Trevena Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
Trevena Inc (NASDAQ:TRVN) Ratings Coverage
Out of 7 analysts covering Trevena Inc (NASDAQ:TRVN), 6 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 86% are positive. Trevena Inc has been the topic of 10 analyst reports since August 3, 2015 according to StockzIntelligence Inc. JMP Securities maintained the shares of TRVN in a report on Wednesday, September 2 with “Buy” rating. The company was initiated on Tuesday, March 29 by FBR Capital. The stock of Trevena Inc (NASDAQ:TRVN) earned “Buy” rating by WallachBeth Capital on Wednesday, March 2. The rating was initiated by Brean Capital with “Buy” on Monday, August 3. The firm has “Outperform” rating by Cowen & Co given on Tuesday, September 1. JMP Securities maintained the stock with “Market Outperform” rating in Wednesday, March 9 report. Barclays Capital upgraded the stock to “Equal-Weight” rating in Tuesday, September 1 report. The firm earned “Buy” rating on Tuesday, August 11 by Needham.
According to Zacks Investment Research, “Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company’s product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania.”
More important recent Trevena Inc (NASDAQ:TRVN) news were published by: Businesswire.com which released: “Trevena, Inc. Receives FDA Breakthrough Therapy Designation for Oliceridine …” on February 22, 2016, also Businesswire.com published article titled: “Trevena, Inc. Announces Proposed Underwritten Offering of Common Stock”, Businesswire.com published: “Trevena, Inc. Announces Pricing of Underwritten Offering of Common Stock” on September 11, 2015. More interesting news about Trevena Inc (NASDAQ:TRVN) was released by: Businesswire.com and their article: “Trevena, Inc. Announces Initiation of Oliceridine Phase 3 Clinical Program …” with publication date: January 19, 2016.
TRVN Company Profile
Trevena Inc., incorporated on November 9, 2007, is a clinical-stage biopharmaceutical company. The Firm discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250. In addition to these three product candidates, it has identified and has completed the Phase I program for TRV734, an orally administered clinical compound expected to be used for first-line treatment of moderate to severe acute and chronic pain.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.